SonicIncytes

George Aliphtiras, CEO george@sonicincytes.com +1 (604) 724-4145

Fatty Liver Disease in the U.S.

Prevalence:

By 2030, 100M Americans with Non-Alcoholic Fatty Liver Disease.


Growth Drivers: Diabetes, obesity & sedentary lifestyle.


Unmet Need: Existing diagnostic tools are expensive, inefficient, inaccurate, inaccessible.

MRI Capabilities In Your Hand

Velacur[™] the world's first handheld 3D liver health assessment tool with diagnostic accuracy comparable to MRI FDA 510(k) Cleared Chronic Liver Disease







Immediate Results: Elasticity and Attenuation

Velacur™ Traction

Customer Pilots:

- 7 centres
- Representing 230 sites



- Multiple drug trials
- \$15B market opportunity

Future:

- Nationwide GI/Hep
- Other specialties & primary care
- International markets

Beth Israel Lahey Health >

Summit Clinical Research

EMORY HEALTHCARE

Medical Center

Northwel

Health*

Madrigal

SGC

ψ

Sonic Incytes An Accomplished Team

Leadership Team



George Aliphtiras, CEO Founder and Former CEO BioMers



Dr. Tim Salcudean Co-founder and CTO

University of British Columbia Professor, Laszlo Chair in Ultrasound and Robotics



Dr. Robert Rohling Co-founder and CSO

University of British Columbia Professor, ICICS Director in Ultrasound and Al



Joseph Lee, CFO



Brian Stachniak Director of Product

Former Manager McKesson Imaging



Jeffrey Haar Director of Sales

Former National Sales Manager Diversatek Health (GI Distributor) Echosens (FibroScan)

Board of Directors

Dr. Kenneth Moritsugu

Former US Deputy Surgeon General Rear Admiral US Public Health Service

Dr. Chris Nguan

Urologist Head Kidney Transplant Vancouver Coastal Health

Daniel Cordingley

Founder and Former CEO Teradici

Natalie Dakers

Founder and Former CEO Accel-Rx and CDRD



If you require further information, please contact us at:

George Aliphtiras, CEO (+1) 604 727 4145 george@sonicincytes.com

> Thank you for your time!



www.sonicincytes.com